The main pathology underlying motor symptoms in Parkinson's disease (PD) is a rather
selective degeneration of nigrostriatal dopamine (DA) neurons. Intrastriatal transplantation …

Clinical studies with intrastriatal transplants of human embryonic mesencephalic tissue have
provided proof-of-principle for the cell replacement strategy in Parkinson's disease (PD) …

In Parkinson's disease (PD), the main pathology is a loss of nigrostriatal dopamine (DA)
neurons. Clinical trials with intrastriatal transplantation of human embryonic mesencephalic …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

The clinical studies with intrastriatal transplants of fetal mesencephalic tissue in Parkinson's
disease (PD) patients have provided proof-of-principle for the cell replacement strategy in …

Cell replacement therapy in Parkinson's disease (PD) has so far been based on the use of
primary dopaminergic (DA) neuroblasts obtained from the brain of aborted human fetuses …

Previous open-label clinical trials have provided proof of principle that intrastriatal
transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional …

Clinical studies involving intrastriatal transplantation of embryonic mesencephalic tissue in
patients with Parkinson disease (PD) have provided proof-of-principle for the cell …

A new therapeutic neurological and neurosurgical methodology involves cell implantation
into the living brain in order to replace intrinsic neuronal systems, that do not spontaneously …

Cell‐based therapies that involve transplantation into the striatum of dopaminergic cells
have attracted considerable interest as possible treatments for Parkinson's disease (PD) …